Agnieszka K. Grabowska
← Zurück zu Team - Ehemalige Labormitglieder
Wissenschaftlicher Lebenslauf
| Since 2018 | Cooperation partner as responsible scientist of Silvacx (Bonn, Heidelberg) |
| 2010 - 2014 | Postdoctoral Scientist, Junior Research Group Immunotherapy and Immunoprevention, DKFZ, Heidelberg |
| 2009 - 2010 | Postdoctoral Scientist and Project Leader, Okairos / Ceinge - Biotecnologie Avanzate s.c. a r.l., Naples, Italy |
| 2007 | Visiting Scientist, Friedrich-Löffler Institute, Tübingen, Germany |
| 2002 - 2009 | PhD student at the Department of Molecular Virology at the Intercollegiate Faculty of Biotechnology, Gdansk, Poland |
| 1997 - 2002 | Studies of Biology at the University of Gdansk, Poland |
Forschungsprojekt
Identification of promiscuous HLA class II-restricted human papillomavirus type 16 E2-, E5-, E6- and E7-derived CD4+ helper T cell epitopes for therapeutic vaccine design
Human papillomavirus (HPV)-specific CD4+ T cell responses were found to play a crucial role in the clearance of HPV-induced malignant lesions. Up to now, therapeutic anti-HPV vaccines have mostly been developed to elicit CD8+T cell responses. HPV T cell epitopes have mostly been determined by indirect methods and for the most prevalent HLA-type, HLA-A2. However, the exclusive targeting of HLA class I-restricted HPV epitopes might not be sufficient, since HLA class I alleles may be downregulated in HPV-induced lesions. Therefore, detailed knowledge about naturally processed HLA class II-restricted HPV epitopes could complement future vaccine design strategies.